Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash & Equivalents: 2011-2024

Historic Cash & Equivalents for RedHill Biopharma (RDHL) over the last 14 years, with Dec 2024 value amounting to $4.6 million.

  • RedHill Biopharma's Cash & Equivalents fell 17.09% to $4.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.6 million, marking a year-over-year decrease of 17.09%. This contributed to the annual value of $4.6 million for FY2024, which is 17.09% down from last year.
  • Latest data reveals that RedHill Biopharma reported Cash & Equivalents of $4.6 million as of FY2024, which was down 17.09% from $5.6 million recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Cash & Equivalents ranged from a high of $29.5 million in FY2021 and a low of $4.6 million during FY2024.
  • Over the past 3 years, RedHill Biopharma's median Cash & Equivalents value was $5.6 million (recorded in 2023), while the average stood at $10.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first climbed by 0.94% in 2020, then slumped by 72.11% in 2023.
  • RedHill Biopharma's Cash & Equivalents (Yearly) stood at $29.3 million in 2020, then increased by 0.61% to $29.5 million in 2021, then plummeted by 32.25% to $20.0 million in 2022, then slumped by 72.11% to $5.6 million in 2023, then fell by 17.09% to $4.6 million in 2024.